{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-26-002932","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2026-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.864471+00:00","generated_at":"2026-05-15T18:47:09.836328+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alzamend Neuro enters $3M at-the-market equity agreement with Ascendiant Capital","bullets":["Up to $3.0M in common stock may be sold periodically via ATM offering with sole agent Ascendiant Capital Markets.","Sales occur under effective shelf registration statement (Form S-3, File No. 333-273610) from August 2023.","Company controls timing, price, and volume; agent uses commercially reasonable efforts with no minimum commitment.","Common stock trades on Nasdaq under ALZN; shares sold will be freely tradable."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-26-002932","json":"https://secwatch.observer/filing/0001214659-26-002932.json","markdown":"https://secwatch.observer/filing/0001214659-26-002932.md","text":"https://secwatch.observer/filing/0001214659-26-002932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465926002932/0001214659-26-002932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465926002932/d362618k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:47:09.836328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8bcd13146f75b64d64199eb3640110eb6863e665","claim":"Alzamend Neuro, Inc. entered into At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC valued at up to $3.0 million (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, Alzamend Neuro, Inc. (the “ Company ”) entered into an At-the-Market Issuance Sales Agreement (the “ Sales Agreement ”) with Ascendiant Capital Markets, LLC, as sales agent (the “ Agent ”) to sell shares of its common stock, par value $0.0001 (the “ Common Stock ”), having an aggregate offering price of up to $3.0 million (the “ Shares ”) from time to time, through an “at the market offering”","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465926002932/0001214659-26-002932-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Ascendiant Capital Markets, LLC"},{"label":"Value","value":"up to $3.0 million"},{"label":"Effective","value":"2026-03-06"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}